# NCT02254785 (NCT02254785)

> Cabazitaxel vs Abiraterone or Enzalutamide in Patients With Poor Prognosis Metastatic Castration-resistant Prostate Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02254785
- Phase: PHASE2
- Status: UNKNOWN
- Sponsor: British Columbia Cancer Agency
- Conditions: Metastatic Castration-Resistant Prostatic Cancer
- Interventions: cabazitaxel; Abiraterone; Enzalutamide 160mg daily (oral)
- Enrollment: 120
- Primary outcome: Clinical benefit rate

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- Bluesky threads: 2
- X threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct02254785